Mahmoud Gaballa
Department of Lymphoma - Myeloma, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2007 | Ain-Shams Faculty of Medicine, Cairo, EGY, MM.B. Ch, Medical School |
Postgraduate Training
| 2020-2021 | Clinical Fellowship, Cellular therapy and Stem Cell Transplantation, MD Anderson Cancer Center, Houston, TX |
| 2017-2020 | Clinical Fellowship, Hematology and Oncology, Baylor College of Medicine, Houston, TX |
| 2011-2014 | Clinical Residency, Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA |
| 2008-2010 | Clinical Residency, Ain Shams University Hospital, Cairo |
Board Certifications
| 2023 | ABIM Oncology |
| 2021 | ABIM Hematology |
| 2016 | American Board of Internal Medicine |
Experience & Service
Academic Appointments
Instructor, Massachusetts General Hospital Cancer Center, Boston, MA, 2021 - 2023
Instructor, Thomas Jefferson University Hospital, Philadelphia, PA, 2015 - 2017
Other Appointments/Responsibilities
Research Fellow, Baylor College of Medicine, Houston, TX, 2019 - 2020
Clinical Elective, John Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, 2014 - Present
Visiting Physician, Thomas Jefferson University Hospital, Philadelphia, PA, 2010 - Present
Research Fellow, Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA, 2010 - 2011
Visiting Physician, MD Anderson Cancer Center, Houston, TX, 2010 - 2010
Clinical Elective, Dana Farber Cancer Institute, Boston, MA, 2010 - 2010
Institutional Committee Activities
Cellular therapy steering committee member, Massachusetts General Hospital IEC Management, 2022 - 2022
Honors & Awards
| 2022 | Program in Clinical Effectiveness Certificate Program, Harvard T.H. Chan School of Public Health |
| 2021 | AACR/ASCO Methods in Clinical Cancer Research Workshop |
| 2021 | ASTCT Clinical Research Training Course |
| 2019 | Fundamentals of Clinical Investigation Course, Baylor College of Medicine |
| 2016 | Jefferson Honors Promotion |
| 2016 | Thomas Jefferson Service Recognition Award |
| 2013 | Jefferson Professionalism Award |
| 2007 | Ain Shams University Honors |
Selected Publications
Peer-Reviewed Articles
- Pasvolsky O, Gaballa MR, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Tang G, Lin P, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14); The MD Anderson Cancer Center Experience. Transplant Cell Ther 29(4):S2666-6367, 2023. e-Pub 2023. PMID: 36646323.
- Dhawale TM, Johnson PC, Gaballa MR, Nelson AM, Lavoie MW, Boateng KY, Greydanus C, Frigault MJ, El-Jawahri A. Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T-cell therapy. Cancer 129(3):441-449, 2023. e-Pub 2022. PMID: 36457279.
- Singh H, Srour SA, Milton DR, McCarty J, Dai C, Gaballa MR, Ammari M, Olivares S, Huls H, De Groot E, Marin D, Petropoulos D, Olson AL, Anderlini P, Im JS, Khouri I, Hosing CM, Rezvani K, Champlin RE, Shpall EJ, Cooper LJN and Kebriaei P. Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies, 2022.
- Gaballa MR, Maus MV. High antigen density of BCMA: Friend or Foe to CAR T cells?, 2022.
- Johnson PC, Jacobson C, Yi A, Gaballa MR, Horick N, Rabideau D, Lindell K, Depinho G, El-Jawahri A, Frigault MJ. Association of Bridging Therapy Utilization with Clinical Outcomes in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy. Journal for ImmunoTherapy of Cancer, 2022.
- Gaballa MR, Ma J, Rauf M, Tanner M, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvani K, Tang G, Lin P, Lee H, Patel K, Kaufmann G, Manasanch EE, Ullah MR, Kebriaei P, Thomas S, Weber D, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH. KRD vs.VRD as Induction before Autologous Hematopoietic Progenitor Cell Transplantation for High-Risk Multiple Myeloma. Bone Marrow Transplant, 2022.
- Gaballa MR, Banerjee PP, Milton DR, Jiang X, Ganesh C, Khazal SJ, Nandivada V, Islam S, Kaplan M, Daher M, Basar R, Alousi A, Mehta RS, Alatrash G, Khouri IF, Oran B, Marin D, Popat UR, Olson AL, Tewari P, Jain N, Jabbour EJ, Ravandi F, Kantarjian HM, Chen K, Champlin RE, Shpall EJ, Rezvani K, Kebriaei P. Blinatumomab maintenance after allogenic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. Blood:1908-19, 2022.
- Gaballa MR, Ma J, Tanner M, Al-Juhaishi T, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvania K, Tang G, Lee H, Patel K, Kaufmann G, Manasanch EE, Ullah MR, Kebriaei P, Thomas S, Weber D, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH.. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma:710-721, 2022.
- Gaballa MR, Kebriaei P. Advances in Cellular Immunotherapy in Hematologic Malignancies. Advances in Oncology:223-236, 2021.
- Gaballa MR, Ramos CA. Cellular Immunotherapy in Lymphoma: Beyond CART Cells. Current treatment options in oncology, 2020.
- Oran AR, Adams CM, Zhang XY, Gennaro VJ, Pfeiffer HK, Mellert HS, Seidel HE, Mascioli K, Kaplan J, Gaballa MR,. Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer. Oncotarget:72395-72414, 2016.
- Alattar ML, Ciccone M, Gaballa MR, Vitale C, Badoux XC, Manoukian G, Keating MJ, Kroll MH, Ferrajoli A. Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia. Leukemia Lymphoma:3452-3454, 2015.
- Gaballa MR, Besa EC. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide. Ann Hematol:723–733, 2014.
- Gaballa M, Farag Y. Predictors of diabetic nephropathy. Open Medicine:287-296, 2013.
- Gaballa MR, Laubach JP, Schlossman RL, Redman K, Noonan K, Mitsiades CS, Ghobrial IM, Munshi N, Anderson KC, Richardson PG. Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol:51-66, 2012.
- Farag YM, Gaballa MR. Diabesity: an overview of a rising epidemic. Nephrol Dial Transplant:28-35, 2011.
Abstracts
- Frigault M, Rosenblatt J, Dhakal B, Raje N, Cook D, Gaballa MR, Emmanuel-Alejandro E, Nissen D, Cornwell C, Banerjee K, Rotte A, Heery C, Avigan D, Jakubowiak A, Bishop M. Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma, 2022.
- Gaballa MR, Ma J, Rauf M, Tanner M, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvania K, Tang G, Lin P, Lee H, Patel K, Kaufmann G, Manasanch EE, Ullah MR, Kebriaei P, Thomas S, Weber D, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH.. KRD vs.VRD as Induction before Autologous Hematopoietic Progenitor Cell Transplantation for High-Risk Multiple Myeloma. Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, 2022.
- Frigault M, Rosenblatt J, Raje N, Cook D, Gaballa M, Emmanuel-Alejandro E, Cornwell C, Banerjee K, Rotte A, Heery C, Avigan D, Jakubowiak A, Bishop M. OAB-003: Phase 1 study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain for the treatment of subjects with relapsed and refractory multiple myeloma, 2022.
- Hester RH, Rivera ZR, Whited LK, Ramdial JL, Aiss MA, Richardson IE, McCray LR, Mbadugha AG, Afrough A, Alsfeld LC, Gaballa MR, Belling M, Franco-Vega M, Vadhan- Raj S, Popat UR. Improving overnight handoffs on the stem cell transplant service through use of an electronic handoff, 2021.
- Gaballa MR, Ma J, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Murphy R, Lee H, Patel K, Kebriaei P, Thomas S, Weber D, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH.. Long-Term Outcomes of Multiple Myeloma Patients Treated with VRD Induction, Autologous Hematopoietic Cell Transplantation with Melphalan 200 Mg/m2 Conditioning, and Lenalidomide Maintenance, 2021.
- Gaballa MR, Al-Juhaishi T, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Murphy R, Lee H, Patel K, Kebriaei P, Thomas S, Weber D, Orlowski RZ, Champlin R, Qazilbash MH. Outcomes of Patients with Multiple Myeloma who Received VRD Induction, Autologous Hematopoietic Cell Transplantation, and Lenalidomide Maintenance, 2020.
- Ramdial JL, Gaballa MR, Al-Juhaishi T. Outcomes in Patients with AL (Light-Chain) Cardiac Amyloidosis. Blood:11-13, 2020.
- Gaballa M, Jang A, Hamad H, Bulsara S, Wu M, Carrum G, Ramos CA, Kamble R, Hill L, Pingali S.R., Vu N, Scholoff A, Obi G, Heslop HE, Lulla PD. Outcomes of myeloablative, T cell deplete unrelated donor hematopoietic stem cell transplantation at a single center. J Clin Oncol, 2020.
- Jang A, Gaballa MR, Hamad H, Bulsara S, Wu M, Kamble R, Ramos CA, Carrum G, Hill L, Vu N, Scholoff A, Obi G, Heslop H, Lulla P. Infection burden in T-cell depleted alternative-donor hematopoietic stem cell transplant recipients compared with recipients of matched related donor HSCT: a single-center experience, 2019.
- Jang A, Huo L, Gaballa M, Hester R, Musunuru T, Chen N, Udden M, Mims M. Double trouble: simultaneous cutaneous lymphomas in an AIDS patient, 2019.
- Kram K, Jang A, Berger S, Gaballa M, Robinson M. Of all the causes of back pain: acute lymphoblastic leukemia presenting with spinal cord compression, 2019.
- Fillmore N, Yellapragada S, White PS, Ifeorah C, Gaballa MR, Rivero G, Pyarajan S, Do N, Brophy M, Munshi N. Lack of racial disparity in outcome of African American (A.A.) and Caucasian patients with symptomatic multiple myeloma (MM) at the Veterans Affairs (V.A.) hospitals. Journal of Clinical Oncology, 2018.
Book Chapters
- Gaballa M, Ramos, CA. Overview of Normal Hematopoiesis. In: Benign Hematology, 1-24, 2019.
Grant & Contract Support
| Title: | T32 Institutional Research Grant at Baylor College of Medicine |
| Funding Source: | T32 Institutional Research Grant at Baylor College of Medicine |
| Role: | Co-Investigator |
| Title: | A Phase I Clinical Trial with TriPRIL CAR T Cells for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma |
| Funding Source: | Glaxo Smith Kline |
| Role: | Co-Investigator |
| Title: | A Phase I Single Arm Clinical Trial of TC-210 T Cells Combined with Immune Checkpoint Inhibitors in Patients with Advanced Mesothlin Expressing Cancers |
| Funding Source: | TCR2 Therapeutics, NCI Repository Program |
| Role: | Co-Investigator |
| Title: | A First-Time-in-Human Open-label Study to Assess Safety and Tolerability of an Autologous anti-CLDN3 CAR-T Cell Therapy (GSK4177000) IV Infusion in Adult Participants with Advanced Cancers |
| Funding Source: | Glaxo Smith Kline |
| Role: | Principal Investigator |
Patient Reviews
CV information above last modified May 29, 2024